Skip to main content

Enliven Therapeutics, Inc.

ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001672619

In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Enliven Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
8 filings
4 insiders, $11.8M in total
Insiders trading
4
Net value
−$11.8M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Enliven Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Enliven Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hohl BenjaminCHIEF FINANCIAL OFFICER38,000Sep 21, 20268
Collins Helen LouiseCHIEF MEDICAL OFFICER25,000Sep 21, 202611
Derynck Mika KDirector0Aug 6, 20262
Kunkel Lori AnneDirector41,884Jul 8, 20264
OrbiMed Advisors LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Capital GP VII LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Genesis GP LLC10% Owner6,555,102IndirectJun 24, 20262
Heyman Richard A.Director22,647IndirectFeb 19, 20264
Garland J. ScottDirector–Feb 17, 20262
Gupta RishiDirector7,663,349IndirectFeb 17, 20261
Bauer JakeDirector87,372Feb 17, 20261
Ballal Rahul D.Director22,341Feb 17, 20261
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER18,750Feb 17, 20268
Patel AnishCHIEF OPERATING OFFICER20,000Feb 17, 20265
Fair Richard A.PRESIDENT AND CEO–Dec 12, 20251
Kintz SamuelPRESIDENT AND CEO890,392IndirectNov 19, 20253
Phillips Andrew JohnDirector–Feb 10, 20250
Schwab Andrew J.10% Owner635,341IndirectFeb 16, 20240
Parmar Kush10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Ventures VI, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I (GP), LLC10% Owner635,341IndirectFeb 16, 20240
5AM Partners VI, LLC10% Owner635,341IndirectFeb 16, 20240
RA Capital Healthcare Fund LPOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Ra Capital Management, L.P.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Kolchinsky PeterOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Shah Rajeev M.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Commodore Capital LP10% Owner1,448,640IndirectFeb 27, 20230
Gray MichaelCFO & COO27,610Feb 22, 20230
Leonard Braden Michael10% Owner1,767,774IndirectJan 5, 20230
Goldfischer CarlDirector–Jun 3, 20220
Mott David MDirector229,224Jun 3, 20220
Bonita David PDirector, 10% Owner4,199,068IndirectJun 3, 20220
Dalton BarbaraDirector–Jun 3, 20220
Conner Edward R.Director–Jun 3, 20220
Chin MarkDirector2,344,072IndirectJun 3, 20220
Williams Laura ADirector–Jun 3, 20220
Kerins Patrick J10% Owner2,611,050Apr 7, 20220
Sandell Scott D10% Owner2,611,050Apr 7, 20220
Baskett Forest10% Owner2,611,050Apr 7, 20220
New Enterprise Associates 14, L.P.10% Owner2,611,050Apr 7, 20220
NEA Partners 14, L.P.10% Owner2,611,050Apr 7, 20220
Nea 14 GP, Ltd10% Owner2,611,050Apr 7, 20220
Sonsini Peter W.10% Owner2,611,050Apr 7, 20220
Florence Anthony A. Jr.10% Owner2,611,050Apr 7, 20220
Attie KennethSVP, CMO34,100Feb 1, 20220
OrbiMed Capital LLCDirector, 10% Owner1,666,666IndirectJul 16, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 28, 2023 (view filing)Dec 262 daysKintz SamuelPresident and CEOSSale−12.0K$14.64−$175.7K−100.0%0 after10b5-1
Jan 2, 2024 (view filing)Dec 28, 2023-Jan 2, 20245 daysHohl BenjaminChief Financial OfficerSSale−11.9K$15.02−$178.3K−100.0%0 after3 lots10b5-1
Jan 2, 2024 (view filing)Dec 28, 2023-Jan 2, 20245 daysPatel AnishChief Operating OfficerSSale−13.5K$15.01−$203.3K−38.0%22.1K after3 lots10b5-1
Jan 3, 2024 (view filing)Dec 29, 20235 daysLyssikatos Joseph PChief Scientific OfficerSSale−12.0K$14.28−$171.4K−100.0%0 after2 lots10b5-1
Jan 24, 2024 (view filing)Jan 222 daysPatel AnishChief Operating OfficerSSale−4.88K$15.14−$73.8K−22.1%17.2K after10b5-1
Jan 29, 2024 (view filing)Jan 254 daysKintz SamuelPresident and CEOSSale−12.0K$15.69−$188.3K−100.0%0 after2 lots10b5-1
Jan 31, 2024 (view filing)Jan 292 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$15.81−$51.4K−100.0%0 after10b5-1
Jan 31, 2024 (view filing)Jan 292 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$15.85−$190.2K−100.0%0 after10b5-1
Feb 1, 2024 (view filing)Jan 302 daysHeyman Richard A.DirectorSSale−1.27K$16.41−$20.8K−0.9%146.0K after10b5-1
Feb 2, 2024 (view filing)4:29 PM ETJan 312 daysSchwab Andrew J. and 5 others10% OwnerSSale−500.0K$15.00−$7.50M−39.3%772.0K after2 lots
Feb 8, 2024 (view filing)Feb 62 daysPatel AnishCHIEF OPERATING OFFICERSSale−4.88K$15.11−$73.7K−28.3%12.3K after10b5-1
Feb 16, 2024 (view filing)4:15 PM ETFeb 142 daysSchwab Andrew J. and 5 others10% OwnerSSale−825.0K$14.90−$12.3M−56.5%635.3K after2 lots
Feb 20, 2024 (view filing)Feb 155 daysHeyman Richard A.DirectorSSale−1.27K$17.42−$22.1K−0.9%144.7K after10b5-1
Feb 28, 2024 (view filing)Feb 262 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$16.89−$202.7K−100.0%0 after2 lots10b5-1
Feb 29, 2024 (view filing)Feb 272 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$16.97−$55.2K−100.0%0 after10b5-1
Mar 4, 2024 (view filing)Feb 294 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$16.42−$197.0K−100.0%0 after2 lots10b5-1
Mar 8, 2024 (view filing)Mar 62 daysPatel AnishCHIEF OPERATING OFFICERSSale−4.88K$15.64−$76.2K−39.5%7.47K after10b5-1
Mar 21, 2024 (view filing)Mar 192 daysHeyman Richard A.DirectorSSale−1.27K$14.50−$18.4K−0.9%143.5K after10b5-1
Mar 22, 2024 (view filing)Mar 202 daysBallal Rahul D.DirectorSSale−13.3K$19.16−$254.4K−37.3%22.3K after10b5-1
Mar 27, 2024 (view filing)Mar 252 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$17.56−$210.7K−100.0%0 after2 lots10b5-1
Mar 29, 2024 (view filing)Mar 272 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$18.25−$59.3K−100.0%0 after2 lots10b5-1
Apr 3, 2024 (view filing)Apr 12 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$18.59−$223.1K−100.0%0 after3 lots10b5-1
Apr 3, 2024 (view filing)Apr 12 daysBallal Rahul D.DirectorSSale−3.24K$19.08−$61.8K−12.7%22.3K after10b5-1
Apr 8, 2024 (view filing)Apr 44 daysBallal Rahul D.DirectorSSale−3.48K$19.15−$66.7K−13.5%22.3K after10b5-1
Apr 10, 2024 (view filing)Apr 82 daysPatel AnishCHIEF OPERATING OFFICERSSale−4.88K$18.60−$90.7K−65.2%2.60K after2 lots10b5-1
Apr 12, 2024 (view filing)Apr 10-112 daysBallal Rahul D.DirectorSSale−67.0K$23.36−$1.57M−75.0%22.3K after4 lots10b5-1
Apr 15, 2024 (view filing)Apr 114 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−20.0K$25.07−$501.4K−100.0%0 after10b5-1
Apr 15, 2024 (view filing)Apr 11-154 daysHeyman Richard A.DirectorSSale−6.32K$24.02−$151.7K−4.4%137.2K after3 lots10b5-1
Apr 15, 2024 (view filing)Apr 114 daysHeyman Richard A.DirectorSSale−649$25.00−$16.2K−2.2%28.6K after10b5-1
Apr 15, 2024 (view filing)Apr 114 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−14.0K$24.73−$346.2K−100.0%0 after2 lots10b5-1
Apr 15, 2024 (view filing)Apr 114 daysKintz SamuelPRESIDENT AND CEOSSale−47.7K$25.04−$1.19M−100.0%0 after10b5-1
Apr 15, 2024 (view filing)Apr 114 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−30.0K$25.04−$751.2K−100.0%0 after10b5-1
Apr 15, 2024 (view filing)Apr 114 daysPatel AnishCHIEF OPERATING OFFICERSSale−17.5K$25.03−$438.0K−100.0%0 after10b5-1
Apr 29, 2024 (view filing)Apr 254 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$16.89−$202.7K−100.0%0 after10b5-1
May 1, 2024 (view filing)Apr 292 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$16.97−$55.2K−100.0%0 after10b5-1
May 1, 2024 (view filing)Apr 292 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$17.91−$214.9K−100.0%0 after2 lots10b5-1
May 7, 2024 (view filing)May 34 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−1.00K$22.50−$22.5K−100.0%0 after10b5-1
May 8, 2024 (view filing)May 62 daysPatel AnishCHIEF OPERATING OFFICERSSale−4.88K$22.72−$110.8K−100.0%0 after10b5-1
May 13, 2024 (view filing)May 94 daysPatel AnishCHIEF OPERATING OFFICERSSale−260$25.06−$6.52K−100.0%0 after10b5-1
May 16, 2024 (view filing)May 142 daysPatel AnishCHIEF OPERATING OFFICERSSale−1.11K$25.00−$27.7K−100.0%0 after10b5-1
May 20, 2024 (view filing)May 164 daysGupta RishiDirector, 10% OwnerSSale−1.03M$22.14−$22.9M−11.9%7.66M after2 lots
May 20, 2024 (view filing)May 164 daysHeyman Richard A.DirectorSSale−1.27K$23.74−$30.1K−0.9%135.9K after10b5-1
May 20, 2024 (view filing)5:00 PM ETMay 164 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerSSale−1.03M$22.14−$22.9M−11.9%7.66M after2 lotsDuplicate filing
May 30, 2024 (view filing)May 282 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−4.25K$23.18−$98.5K−100.0%0 after3 lots10b5-1
May 30, 2024 (view filing)May 282 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$23.18−$278.2K−100.0%0 after3 lots10b5-1
May 31, 2024 (view filing)May 292 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.0K$21.73−$260.8K−100.0%0 after2 lots10b5-1
Jun 10, 2024 (view filing)Jun 64 daysPatel AnishCHIEF OPERATING OFFICERSSale−1.13K$20.06−$22.7K−100.0%0 after10b5-1
Jun 20, 2024 (view filing)Jun 173 daysHeyman Richard A.DirectorSSale−1.27K$21.48−$27.3K−0.9%134.6K after10b5-1
Jun 27, 2024 (view filing)Jun 252 daysKintz SamuelPRESIDENT AND CEOSSale−12.0K$21.66−$259.9K−1.1%1.08M after2 lots10b5-1
Jul 1, 2024 (view filing)Jun 274 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−4.25K$22.57−$95.9K−100.0%0 after3 lots10b5-1